🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)

Recruitingn/aAges 3 Years - 14 YearsFemaleErasme University Hospital
NCT02595255 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk. The primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients from 3 to 14 year old included - Belong to one of these 3 groups (modified from Wallace et al, 2005): * High risk : Conditioning therapy for bone marrow transplantation or pelvic irradiation * Moderate/Low risk : Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma. * No risk (control group) : patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment. Exclusion Criteria: * CNS (central nervous system) irradiation, cerebral tumour * Current or previous ovarian disease/surgery * Familial history of premature ovarian failure (no iatrogenic or surgical origins) * Previous known severe chronic disease potentially affecting normal growth or puberty (diseases inducing malnutrition, anorexia, genetic/congenital disorders as Turner, Kallman, BPES(Blepharophimosis, ptosis, and epicanthus inversus syndrome) syndromes, uncontrolled severe diabetes, Cushing Syndrome, auto-immune diseases, cystic fibrosis, severe renal dysfunction) * Genetic/congenital disorders inducing mental retardation
💊

What it tests

  • No intervention
📍

Where

8 sites
Centre Hospitalier Chrétien (CHC)- Clinique de l'espérance
Montegnée, Belgium
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
Hôpital Universitaire Reine Fabiola (HUDERF)
Brussels, Belgium
Universitair Ziekenhuis Brussels
Brussels, Belgium
Universitair Ziekenhuis Leuven
Leuven, Belgium
Centre Hospitalier Régional (CHR)-Citadelle
Liège, Belgium
Centre Oscar Lambret
Lille, France
CHRU Lille-Hôpital Jeanne de Flandre
Lille, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy